SCHEMBL145990

SCHEMBL145990

Cc1cc(C(=O)N2CCN(C)CC2)[nH]c1/C=C1\C(=O)Nc2ccc(S(=O)(=O)Cc3ccccc3)cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 4/20 0.53
SRC P12931 12/20 0.52
AURKA O14965 2/20 0.51
KDR P35968 7/20 0.51
FGFR1 P11362 5/20 0.51
MEN1 O00255 2/20 0.51
CDK2 P24941 2/20 0.51
KMT2A Q03164 2/20 0.51
PTK2B Q14289 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
CCNE1 P24864 1/20 0.51
RECQL P46063 1/20 0.51
LCK P06239 5/20 0.49
YES1 P07947 5/20 0.49
PDGFRB P09619 5/20 0.49
FYN P06241 4/20 0.49
RET P07949 2/20 0.46
PLK4 O00444 1/20 0.43
RIOK3 O14730 1/20 0.43
CASK O14936 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142474 0.82 MET (0.55) METSRCAURKAKDRFGFR1
SCHEMBL5396446 0.82 MET (0.77) METSRCAURKAKDRFGFR1
SCHEMBL141995 0.81 RET (0.61) SRCAURKAKDRFGFR1MEN1
SCHEMBL141818 0.80 KDR (0.67) METSRCAURKAKDRFGFR1
SCHEMBL144583 0.80 MET (0.63) METSRCKDRFGFR1MEN1
SCHEMBL142117 0.80 MET (0.63) METSRCAURKAKDRFGFR1
SCHEMBL7125587 0.80 KDR (0.65) METSRCAURKAKDRFGFR1
SCHEMBL144668 0.79 KDR (0.70) METSRCKDRFGFR1MEN1
SCHEMBL139941 0.79 MET (0.64) METSRCKDRFGFR1MEN1
SCHEMBL144903 0.79 MET (0.64) METSRCAURKAKDRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
WO-2005065686-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) 2005-07-21 WO disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 MET 310/4885SRC 2611/4885AURKA 4579/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 MET 310/4885SRC 2611/4885AURKA 4579/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 MET 151/4885SRC 75/4885AURKA 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.